As components of PI3K/AKT pathways are widely mutated and hypersactivated in human cancer and because E6/E7 oncoproteins stimulate the AKT signaling, AKT phosphorylation of EZH2 inhibits its activity [268,269,270], contributing to the loss of corepressive activity of EZH2 and in-turn, de-repression of cancer relevant genes. The gene discussed is EZH2; the disease is cancer.